Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma

Katelyn Stepan; Ethan Craig; Scott Andrew Skillington; Brian C. Deutsch; Stephanie Chen; Nneoma S. Wamkpah; Craig A. Bollig; Dorina Kallogjeri; Wade L. Thorstad; Sidharth V. Puram; Patrik Pipkorn; Ryan S. Jackson

doi:10.1002/hed.27002

Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma

Katelyn Stepan, Ethan Craig, Scott Andrew Skillington, Brian C. Deutsch, Stephanie Chen, Nneoma S. Wamkpah, Craig A. Bollig, Dorina Kallogjeri, Wade L. Thorstad, Sidharth V. Puram, Patrik Pipkorn, Ryan S. Jackson

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC. Methods: A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/− adjuvant therapy at a single center between 1996 and 2018. Results: Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0–173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08–0.78). There was no difference in overall or disease-free survival between those with and without SPM. Conclusion: The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.

Original language	English
Pages (from-to)	1069-1078
Number of pages	10
Journal	Head and Neck
Volume	44
Issue number	5
DOIs	https://doi.org/10.1002/hed.27002
State	Published - May 2022

Keywords

HPV
oropharynx
second primary
squamous cell carcinoma
transoral surgery

Access to Document

10.1002/hed.27002

Cite this

Stepan, K., Craig, E., Skillington, S. A., Deutsch, B. C., Chen, S., Wamkpah, N. S., Bollig, C. A., Kallogjeri, D., Thorstad, W. L., Puram, S. V., Pipkorn, P., & Jackson, R. S. (2022). Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma. Head and Neck, 44(5), 1069-1078. https://doi.org/10.1002/hed.27002

@article{6b3b0fb29f3b4b9885ccedac61a85926,

title = "Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma",

abstract = "Background: Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC. Methods: A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/− adjuvant therapy at a single center between 1996 and 2018. Results: Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0–173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08–0.78). There was no difference in overall or disease-free survival between those with and without SPM. Conclusion: The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.",

keywords = "HPV, oropharynx, second primary, squamous cell carcinoma, transoral surgery",

author = "Katelyn Stepan and Ethan Craig and Skillington, {Scott Andrew} and Deutsch, {Brian C.} and Stephanie Chen and Wamkpah, {Nneoma S.} and Bollig, {Craig A.} and Dorina Kallogjeri and Thorstad, {Wade L.} and Puram, {Sidharth V.} and Patrik Pipkorn and Jackson, {Ryan S.}",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = may,

doi = "10.1002/hed.27002",

language = "English",

volume = "44",

pages = "1069--1078",

journal = "Head and Neck",

issn = "1043-3074",

number = "5",

}

Stepan, K, Craig, E, Skillington, SA, Deutsch, BC, Chen, S, Wamkpah, NS, Bollig, CA, Kallogjeri, D , Thorstad, WL , Puram, SV , Pipkorn, P & Jackson, RS 2022, 'Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma', Head and Neck, vol. 44, no. 5, pp. 1069-1078. https://doi.org/10.1002/hed.27002

TY - JOUR

T1 - Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma

AU - Stepan, Katelyn

AU - Craig, Ethan

AU - Skillington, Scott Andrew

AU - Deutsch, Brian C.

AU - Chen, Stephanie

AU - Wamkpah, Nneoma S.

AU - Bollig, Craig A.

AU - Kallogjeri, Dorina

AU - Thorstad, Wade L.

AU - Puram, Sidharth V.

AU - Pipkorn, Patrik

AU - Jackson, Ryan S.

PY - 2022/5

Y1 - 2022/5

N2 - Background: Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC. Methods: A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/− adjuvant therapy at a single center between 1996 and 2018. Results: Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0–173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08–0.78). There was no difference in overall or disease-free survival between those with and without SPM. Conclusion: The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.

AB - Background: Little data exists regarding the incidence of oropharyngeal and upper aerodigestive tract (UADT) second primary malignancies (SPM) among human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here we evaluate SPM rates among patients with HPV-related OPSCC. Methods: A retrospective cohort study of 412 patients with HPV-related OPSCC who underwent transoral resection +/− adjuvant therapy at a single center between 1996 and 2018. Results: Twenty patients (4.9%) developed SPM of the UADT, nine (2.2%) occurring in the oropharynx. Median time to diagnosis was 59.5 months (0–173 months). Risk of SPM was lower for patients receiving adjuvant radiation (aHR: 0.25, 95%CI: 0.08–0.78). There was no difference in overall or disease-free survival between those with and without SPM. Conclusion: The rate of SPM among patients with HPV-positive OPSCC is lower than reported rates among HPV-negative OPSCC. To date, this is the largest study evaluating SPM in patients with surgically treated HPV-positive OPSCC.

KW - HPV

KW - oropharynx

KW - second primary

KW - squamous cell carcinoma

KW - transoral surgery

UR - http://www.scopus.com/inward/record.url?scp=85124716742&partnerID=8YFLogxK

U2 - 10.1002/hed.27002

DO - 10.1002/hed.27002

M3 - Article

C2 - 35175648

AN - SCOPUS:85124716742

SN - 1043-3074

VL - 44

SP - 1069

EP - 1078

JO - Head and Neck

JF - Head and Neck

IS - 5

ER -

Development of second primary malignancies after transoral surgery in human papilloma virus-positive oropharyngeal squamous cell carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this